This program will discuss how clinical evidence supports the use of VELCADE (bortezomib) in patients with previously untreated and relapsed multiple myeloma. Attendees will learn how to establish a plan for length of therapy with VELCADE, as well as patient management strategies, including subcutaneous administration.
Registration opens at 6:30 pm, with the program to start at 7 pm. To register in advance, please email epic@theselvagroup.com.
This is hosted by Millennium: The Takeda Oncology Company.
